Navigation Links
Better treatment selection and improved therapies -- key to improving prognosis in acute HF
Date:5/30/2009

Today, acute heart failure represents the most common reason for hospitalisation in the over-65 population. Although hospital care improves symptoms in the first 24 hours after admission in around 50% of these patients, acute heart failure events still remain associated with a more than 50% mortality and rehospitalisation rate at 6-12 months. "Indeed," says Professor Marco Metra from the Cardiology Department of the University of Brescia, Italy, "it is the very rapid onset of symptoms and the need for urgent therapy which characterise the condition."1,2

Treatments in acute heart failure, he adds, have not undergone any great change in recent decades, despite the demand of heart failure's increasing prevalence and huge personal and public impact. Professor Metra said that treatments are still based on loop diuretics (furosemide), peripheral vasodilators (nitrates) and inotropic agents. Even the more recently approved treatments, he added, such as levosimendan in Europe and nesiritide in the USA, have been associated with uncertain effects on outcomes in randomised trials. "So hospitalisations for acute heart failure are still associated with high mortality and rehospitalisation rates," he says. "The burden is tremendous because of the large number of patients involved, their poor prognosis and the costs of the treatment."

In a presentation at Heart Failure Congress 2009 Professor Metra defined two major pathways along which this burden might be reduced and treatment improved:

* Better selection of treatments. To date, he said, therapy in acute heart failure has been administered with little attention to the clinical presentation of each patient. Guidelines on heart failure issued by the European Society of Cardiology in 2008 define heart failure as a heterogeneous condition and recommend that different therapies are used on the basis of clinical presentation; for example, patients with fluid overload should undergo fluid removal throu
'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. Struggling male readers respond better to female teachers
6. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
7. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
8. Researchers Find Better Way to Deliver Blood Thinner
9. Clinical trials present better alternatives for dialysis patients
10. New nurses report job stress, need for better management
11. Hispanics hypertension better controlled with equal access to care
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Mayo Clinic study reveals rural, unmarried women at higher risk for depression 2Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:Chemical engineering researchers identify biofilms that cause infections 2Health News:Chemical engineering researchers identify biofilms that cause infections 3Health News:Chemical engineering researchers identify biofilms that cause infections 4Health News:Study aims to improve sex education for deaf pupils 2Health News:Study aims to improve sex education for deaf pupils 3Health News:Chair of Radiology at Presbyterian Hospital of Dallas Named President of American College of Physician Executives 2Health News:Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success 2Health News:Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success 3Health News:Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success 4
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4MTVS GYT Campaign Spurs Nationwide Movement to Get Yourself Tested 47670 1MTVS GYT Campaign Spurs Nationwide Movement to Get Yourself Tested 47670 2MTVS GYT Campaign Spurs Nationwide Movement to Get Yourself Tested 47670 3MTVS GYT Campaign Spurs Nationwide Movement to Get Yourself Tested 47670 4MTVS GYT Campaign Spurs Nationwide Movement to Get Yourself Tested 47670 5MTVS GYT Campaign Spurs Nationwide Movement to Get Yourself Tested 47670 6Astellas Hires New Vice President of Compliance 47666 1Astellas Hires New Vice President of Compliance 47666 2Scientists use bed bugs own chemistry against them 47664 1Scientists use bed bugs own chemistry against them 47664 2Scientists use bed bugs own chemistry against them 47664 3Scientists use bed bugs own chemistry against them 47664 4